Lumiblast SIGNED
A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Lumiblast project word cloud
Explore the words cloud of the Lumiblast project. It provides you a very rough idea of what is the project "Lumiblast" about.
Project "Lumiblast" data sheet
The following table provides information about the project.
| Coordinator |
OSLO UNIVERSITETSSYKEHUS HF
Organization address contact info |
| Coordinator Country | Norway [NO] |
| Project website | http://www.lumiblast.eu |
| Total cost | 3˙031˙375 € |
| EC max contribution | 3˙031˙375 € (100%) |
| Programme |
1. H2020-EU.1.2.1. (FET Open) |
| Code Call | H2020-FETOPEN-2014-2015-RIA |
| Funding Scheme | RIA |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-10-01 to 2021-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | OSLO UNIVERSITETSSYKEHUS HF | NO (OSLO) | coordinator | 1˙306˙375.00 |
| 2 | KNIGHT SCIENTIFIC LIMITED | UK (PLYMOUTH DEVON) | participant | 477˙500.00 |
| 3 | UNIVERSITAT POLITECNICA DE VALENCIA | ES (VALENCIA) | participant | 424˙375.00 |
| 4 | ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON | EL (ATHINA) | participant | 413˙125.00 |
| 5 | UNIVERSITETET I OSLO | NO (OSLO) | participant | 410˙000.00 |
Map
Project objective
Brain cancers such as glioblastoma multiforme (GBM) are practically incurable due to their location, invasiveness and highly aggressive nature. The use of light-based treatments of GBM by activating tumor-localized photosensitizers, such as in photodynamic therapy (PDT) has been clinically evaluated, but with limited success. This is mainly due to the limited penetration of light into tissue and the efficient spread of tumor cells typically up to at least 2 cm from the resection margin. Moreover, the existing photon based treatments (photodynamic therapy) are highly invasive and usually require open-cranium surgery, due to the need for external light sources. In the Lumiblast project the photons are produced inside the tumor cells in the form of chemiluminescence avoiding the major limitation of using external light to treat solid, deep-sited and inaccessible tumors. The principle utilized in Lumiblast may also be relevant for cancers of other origins. Due to its nature Lumiblast is expected to act on individual cells, rather than the collective lesion; it could thus completely eliminate the hitherto incurable GBM. Each GBM cell is expected to become a small lamp providing the light required for the photosensitive agents to become activated, killing the tumour cells from the inside. Lumiblast requires a concerted interdisciplinary action. The project coordinator (Berg’s group, Oslo University Hospital, OUS) is world renowned in PDT and photomedicine, while the team from the University of Athens (Georgios Vougioukalakis’ group, UoA) is up and coming with high expertise in synthetic chemistry. The Polytechnic University of Valencia (Miguel Miranda’s group, UPV) team is headed by a world leader in Photochemistry, the University of Oslo partner (Hanne H. Tønnensen’s group, UiO) is specialized in pharmaceutical formulation, and Knight Scientific Ltd (KSL, CEO Jan Knight) is an SME with an impressive track record in ROS-activated luminescence. This 4.5-year project will establish the Lumiblast breakthrough technology by providing proof-of-concept in extracellular systems, GBM cell cultures and animal models, with the vision to advance Lumiblast to the clinic 5-6 years after the end of the proposed project.
Deliverables
| Project website | Websites, patent fillings, videos etc. | 2019-05-31 16:51:01 |
Take a look to the deliverables list in detail: detailed list of Lumiblast deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Pantelia, Daskalaki, Cuquerella, Rotas, Miranda, Vougioukalakis Synthesis and Chemiluminescent Properties of Amino-Acylated luminol Derivatives Bearing Phosphonium Cations published pages: 3957, ISSN: 1420-3049, DOI: 10.3390/molecules24213957 |
Molecules 24/21 | 2020-04-04 |
| 2020 |
Mantas Grigalavicius, Maria Mastrangelopoulou, Delmon Arous, Asta Juzeniene, Mathilde Ménard, Ellen Skarpen, Kristian Berg, Theodossis A. Theodossiou Photodynamic efficacy of cercosporin in 3D tumor cell cultures published pages: , ISSN: 0031-8655, DOI: 10.1111/php.13257 |
Photochemistry and Photobiology | 2020-04-04 |
| 2019 |
Maria Mastrangelopoulou, Mantas Grigalavicius, Kristian Berg, Mathilde Ménard, Theodossis A. Theodossiou Cytotoxic and Photocytotoxic Effects of Cercosporin on Human Tumor Cell Lines published pages: 387-396, ISSN: 0031-8655, DOI: 10.1111/php.12997 |
Photochemistry and Photobiology 95/1 | 2019-04-18 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMIBLAST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LUMIBLAST" are provided by the European Opendata Portal: CORDIS opendata.